logo-loader
HealthPharma & Biotech
Allergy Therapeutics PLC

Allergy Therapeutics thinks its adjuvant system could be used in fight against cancer

The combination of Allergy’s Microcrystalline Tyrosine (MCT) adjuvant system with virus-like particles proved successful in mice

skin cancer
MCT has been used for years to boost the immune system of allergy sufferers

Early-stage research has shown that Allergy Therapeutics PLC’s (LON:AGY) adjuvant technology could potentially be used in the fight against cancer.

Allergy’s Microcrystalline Tyrosine (MCT) adjuvant system has long been used to help boost the immune systems of allergy sufferers.

But research carried out alongside the University of Oxford has shown that the combination of MCT and virus-like particles (VLPs) could potentially benefit people with cancer.

READ: Allergy Thera well-funded and making headway

The combination caused tumour regression in an “aggressive” melanoma (skin cancer) mouse model and initiated a “highly protective” immune response.

Typically, VLPs are quickly ‘washed away’ by the body due to their small size, but formulating them with bigger MCT meant they were exposed to the immune system for longer. This helped to induce “strong” responses from T-cells – a type of white blood cell that attacks cancer cells.

“Our strategy for growth with our adjuvant division, Bencard Adjuvant Systems, focuses on extending the use of MCT and VLPs in developing vaccines for unmet needs and disease areas beyond allergy that require an effective depot adjuvant,” said chief executive Manuel Llobet.

“This ground-breaking work, completed in collaboration with the Jenner Institute at the University of Oxford, supports this strategy and complements the existing work illustrating the potential of our adjuvant systems in disease areas such as influenza and malaria.”

Allergy shares were broadly flat at 9.2p on Tuesday.

Quick facts: Allergy Therapeutics PLC

Price: £0.13

Market: AIM
Market Cap: £82.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read